CC
EIGR

Carlson Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Carlson Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,333
Closed -$82.6K – 146
2022
Q4 		$82.6K Buy
2,333
+500
+27% +$60.1K 0.01% 117
2022
Q3 		$414K Sell
1,833
-334
-15% -$82.1K 0.03% 116
2022
Q2 		$410K Buy
2,167
+1,267
+141% +$255K 0.03% 118
2022
Q1 		$224K Sell
900
-1,833
-67% -$290K 0.02% 150
2021
Q4 		$426K Buy
+2,733
New +$529K 0.02% 138

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Carlson Capital's EIGR Position: Q1 2023 in Review

Carlson Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2023, closing a stake of 2,333 shares — an estimated $82.6K sold.

Carlson Capital first reported a position in EIGR in Q4 2021 and held it in 5 quarters. The position peaked at $426K in Q4 2021. 71 funds tracked by Wall St. Rank hold EIGR as of Q1 2023.

  • Carlson Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Carlson Capital sold 2,333 Eiger BioPharmaceuticals, Inc. shares in Q1 2023, an estimated $82.6K.
  • Carlson Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
  • Carlson Capital's Eiger BioPharmaceuticals, Inc. position peaked at $426K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2023.

Based on Carlson Capital's 13F filing for Q1 2023, filed 12 May 2023.